Acute Respiratory Distress Syndrome (ARDS)

01Pathophysiology

ARDS represents the lung's stereotyped inflammatory response to a variety of insults, whether originating from within the lung (direct injury) or from distant organ systems (indirect injury). The unifying pathology is diffuse alveolar damage (DAD), which progresses through three overlapping phases.

In the exudative phase (days 1 to 7), the triggering insult activates alveolar macrophages and recruits neutrophils into the pulmonary microvasculature. These neutrophils release reactive oxygen species, proteases, and pro-inflammatory cytokines (IL-1, IL-6, IL-8, TNF-alpha) that injure both the capillary endothelium and the alveolar epithelium. This dual injury disrupts the normally tight alveolar-capillary barrier, allowing protein-rich edema fluid to flood the alveolar spaces. The leaked plasma proteins, combined with necrotic cellular debris from damaged type I pneumocytes, polymerize along the alveolar surface to form hyaline membranes, which are the histological hallmark of ARDS. Simultaneously, injury to type II pneumocytes reduces surfactant production, increasing alveolar surface tension and promoting widespread alveolar collapse (atelectasis).

This combination of flooded and collapsed alveoli creates regions of the lung where blood flows through capillaries but encounters no ventilated alveolar units. This is true intrapulmonary shunt ($V\mathrm{/}Q=0V/Q\; =\; 0$), which is the reason hypoxemia in ARDS is refractory to supplemental oxygen. Unlike hypoxemia from V/Q mismatch (which responds to increased $Fi{O}_{2}FiO\_2$), shunt-mediated hypoxemia cannot be corrected by simply delivering more oxygen because the gas never reaches the blood. This concept is central to understanding why these patients require positive pressure ventilation with PEEP rather than a nasal cannula or face mask.

During the proliferative phase (days 7 to 21), the lung attempts repair. Type II pneumocytes proliferate and differentiate into type I cells to re-establish the alveolar lining. Fibroblasts begin organizing the intra-alveolar exudate. Some patients recover during this phase, while others progress.

In the fibrotic phase (beyond day 21), a subset of patients develops extensive interstitial fibrosis and architectural distortion. This leads to reduced lung compliance, persistent ventilator dependence, and a poor prognosis. The presence of this late fibrotic remodeling explains why survivors of prolonged ARDS may have lasting impairment in pulmonary function.

02Classification and Clinical Manifestation

Berlin Definition Classification (2012)

The Berlin criteria replaced the older American-European Consensus Conference (AECC) definition. Classification is based entirely on the severity of oxygenation impairment, measured by the $Pa{O}_2\mathrm{/}Fi{O}_{2}PaO\_2/FiO\_2$ (P/F) ratio while the patient receives a minimum PEEP of $\ge 5\backslash geq\; 5$ cmH${}_2\_2$O.

Berlin Criteria Components

Direct vs. Indirect Causes

03Diagnostic Workup

The diagnostic approach to ARDS is fundamentally clinical, meaning there is no single confirmatory laboratory test or biopsy required. The diagnosis is established by demonstrating that the patient meets all four Berlin criteria simultaneously.

The best initial step when you suspect ARDS is obtaining an ABG and a chest radiograph together. The ABG will reveal the degree of hypoxemia and allow calculation of the P/F ratio, which is the cornerstone of diagnosis and severity classification. The $A\text{-}aA\backslash text\{-\}a$ gradient will be elevated, confirming that the hypoxemia is due to a parenchymal process rather than hypoventilation. Early in the course, the ABG often shows a respiratory alkalosis (low $PaC{O}_{2}PaCO\_2$) from compensatory tachypnea; progression to respiratory acidosis indicates fatigue or worsening disease.

The chest radiograph should show bilateral opacities that cannot be fully accounted for by pleural effusions, atelectasis, or lung nodules. In classic presentations, the CXR demonstrates diffuse "white-out" involving both lung fields. However, early or mild ARDS may present with patchy bilateral infiltrates that can be subtle.

A CT scan of the chest is not required for diagnosis but provides important information. It reveals the heterogeneous nature of ARDS: consolidation predominates in dependent (posterior) lung regions due to gravitational effects on the edematous lung, while non-dependent (anterior) regions may show ground-glass opacities or even relatively normal-appearing lung. This heterogeneity is the physiological rationale behind prone positioning, as flipping the patient redistributes perfusion toward the better-aerated anterior lung.

Echocardiography is essential to exclude cardiogenic pulmonary edema, which is the primary differential diagnosis. The Berlin criteria require objective exclusion of cardiac failure if no clear ARDS risk factor is identified. Echo showing normal LV systolic function and no evidence of elevated left-sided filling pressures supports ARDS. A low BNP or NT-proBNP further supports the non-cardiogenic origin, though values can overlap in critically ill patients.

The pulmonary artery catheter (Swan-Ganz) demonstrating a pulmonary capillary wedge pressure (PCWP) $\le 18\backslash leq\; 18$ mmHg was previously considered a defining feature under the AECC criteria. The Berlin definition no longer mandates catheterization, but the concept remains testable: ARDS produces low-pressure pulmonary edema in contrast to heart failure.

Finally, identifying the underlying cause is critical for management. Blood cultures, sputum cultures, and relevant imaging should be pursued to guide targeted therapy (e.g., antibiotics for pneumonia or sepsis).

04Management and Treatment

Acute stabilization centers on two parallel priorities: supporting gas exchange through protective mechanical ventilation and treating the precipitating cause.

Lung-protective ventilation is the single most important intervention with proven mortality benefit. The ARDSNet protocol mandates a tidal volume of $6mL\mathrm{/}kg6\backslash \; mL/kg$ of ideal (predicted) body weight, NOT actual body weight. Ideal body weight is calculated using height:

$$IB{W}_{male}=50+2.3\times (heightininches-60)IBW\_\{male\}\; =\; 50\; +\; 2.3\; \backslash times\; (height\backslash \; in\backslash \; inches\; -\; 60)$$

$$IB{W}_{female}=45.5+2.3\times (heightininches-60)IBW\_\{female\}\; =\; 45.5\; +\; 2.3\; \backslash times\; (height\backslash \; in\backslash \; inches\; -\; 60)$$

The rationale is that ARDS lungs have markedly reduced aerated volume (the "baby lung" concept), so delivering conventional tidal volumes ($10\text{-}12mL\mathrm{/}kg10\backslash text\{-\}12\backslash \; mL/kg$) overdistends the remaining functional alveoli, causing ventilator-induced lung injury (VILI) through volutrauma and biotrauma. The plateau pressure must be maintained below 30 cmH${}_2\_2$O to prevent overdistension. Permissive hypercapnia (tolerating elevated $PaC{O}_{2}PaCO\_2$ up to ~50-60 mmHg, pH $\ge 7.25\backslash geq\; 7.25$) is accepted as a trade-off for protective ventilation.

PEEP is titrated using the ARDSNet PEEP-$Fi{O}_{2}FiO\_2$ tables to maintain $Sp{O}_{2}SpO\_2$ between 88-95% (or $Pa{O}_{2}PaO\_2$ 55-80 mmHg). Higher PEEP recruits collapsed alveoli, improves V/Q matching, and allows reduction in $Fi{O}_{2}FiO\_2$ (thereby reducing oxygen toxicity). The oxygenation target is deliberately conservative; there is no benefit to achieving supranormal $Pa{O}_{2}PaO\_2$.

Prone positioning should be initiated early (within 12 to 24 hours) in patients with moderate-to-severe ARDS ( mmHg). The PROSEVA trial demonstrated a mortality reduction from approximately 33% to 16% when patients were placed prone for at least 16 hours per day. Proning works by redistributing ventilation toward dorsal lung regions that receive preferential perfusion, reducing V/Q mismatch and improving recruitment of dependent atelectatic zones.

Conservative fluid management (as demonstrated in the FACTT trial) aims for an even or negative fluid balance once the patient is hemodynamically stable. Excess intravascular volume worsens pulmonary edema and prolongs ventilator dependence. This does not apply during active septic shock resuscitation, where initial fluid resuscitation takes priority.

Neuromuscular blockade with cisatracurium (15 mg IV bolus followed by a continuous infusion of 37.5 mg/hr for 48 hours) may be considered in early severe ARDS (). The ACURASYS trial showed mortality benefit, though the subsequent ROSE trial using a light sedation strategy in the control group did not replicate this. Blockade prevents ventilator dyssynchrony and reduces oxygen consumption, but prolonged use carries the risk of ICU-acquired weakness.

Corticosteroids remain an evolving area. Dexamethasone (20 mg IV daily for 5 days, then 10 mg IV daily for 5 days) showed mortality benefit in early moderate-to-severe ARDS. Methylprednisolone (1 mg/kg/day with taper over 2 to 3 weeks) has also been studied for persistent ARDS beyond day 7. A critical caveat: steroids should not be initiated after day 14 of ARDS onset, as late administration has been associated with worse outcomes.

Venovenous ECMO is a rescue therapy for patients with refractory hypoxemia (typically ) who fail to improve despite optimal ventilation, proning, and adjunctive measures. It is best offered at experienced ECMO centers and should be considered early rather than as a last resort.

Throughout all of this, treating the underlying cause (antibiotics for infection, surgical source control, stopping a causative transfusion or drug) is non-negotiable.

Contraindications and Cautions

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The most common way students miss ARDS questions is by confusing it with cardiogenic pulmonary edema. Both present with bilateral white-out on CXR and acute hypoxemia. The vignette will embed clues to differentiate: a patient with cardiogenic edema will have a history of heart failure, jugular venous distension, an S3 gallop, and peripheral edema, and will respond to diuretics. The ARDS vignette, by contrast, will describe a preceding insult (sepsis, pneumonia, pancreatitis, trauma, aspiration) with no signs of volume overload. If the question mentions a normal echocardiogram or a low BNP, it is steering you toward ARDS.

A second common trap involves the tidal volume calculation. Students frequently select $6mL\mathrm{/}kg6\backslash \; mL/kg$ of actual body weight, which overestimates the appropriate tidal volume in obese patients. Lung size correlates with height, not weight. The exam will present an obese patient and test whether you calculate tidal volume using ideal body weight derived from height. An 80 kg woman who is 5'4" has an ideal body weight of approximately 54.5 kg, yielding a target tidal volume of approximately 327 mL, not 480 mL.

A third area of confusion is the oxygenation target. Students trained to normalize oxygen saturation may select interventions aiming for $Sp{O}_{2}SpO\_2$ of 100%. In ARDS, the accepted target is $Sp{O}_{2}SpO\_2$ 88-95% (or $Pa{O}_{2}PaO\_2$ 55-80 mmHg). Driving for higher targets requires either higher $Fi{O}_{2}FiO\_2$ (risking oxygen toxicity) or higher pressures (risking barotrauma and VILI), both of which worsen outcomes.

Finally, students forget the timing criterion of the Berlin definition. ARDS must develop within one week of a recognized clinical insult. A patient with bilateral infiltrates and hypoxemia developing gradually over several weeks does not meet the definition and should prompt consideration of alternative diagnoses such as interstitial lung disease, cryptogenic organizing pneumonia, or lymphangitic carcinomatosis.

The core competency tested across ARDS questions is the ability to recognize non-cardiogenic pulmonary edema following a systemic or pulmonary insult, apply the Berlin classification correctly, and select lung-protective ventilation with the appropriate tidal volume calculation as the first-line intervention.